Immunitybio, Inc. (IBRX) — SEC Filings
Immunitybio, Inc. (IBRX) — 35 SEC filings. Latest: 10-Q (May 7, 2026). Includes 24 8-K, 6 10-Q, 2 DEF 14A.
View Immunitybio, Inc. on SEC EDGAR
Overview
Immunitybio, Inc. (IBRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 9, 2026: ImmunityBio, Inc. filed an 8-K on April 9, 2026, reporting its financial results and condition. The filing includes exhibits such as financial statements and a company logo. The company's mailing and business address is 3530 John Hopkins Court, San Diego, CA 92121.
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 1 bearish, 31 neutral, 3 mixed. The dominant filing sentiment for Immunitybio, Inc. is neutral.
Filing Type Overview
Immunitybio, Inc. (IBRX) has filed 6 10-Q, 24 8-K, 2 DEF 14A, 2 10-K, 1 SC 13D/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of IBRX's 29 recent filings, 1 were flagged as high-risk, 18 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $4.5M |
| Net Income | -$105.8M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | N/A |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. Patrick Soon-Shiong
- Dr. Richard Adkerson
Industry Context
The biotechnology sector is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Companies like ImmunityBio compete in a landscape where innovation is paramount, but success is often dependent on securing substantial funding and navigating complex clinical trials and approval processes.
Top Tags
filing (9) · material-agreement (7) · financials (6) · corporate-governance (5) · 10-Q (4) · sec-filing (3) · ImmunityBio (3) · 8-k (2) · regulation-fd (2) · 8-K (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| 8-K Document Size | 26061 | Size of the main 8-K filing in KB. |
| EX-99.1 Document Size | 20447 | Size of Exhibit 99.1 in KB, likely containing the core disclosure. |
| SEC File Number | 001-37507 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 43-1979754 | Company's tax identification number. |
| Net Loss | $105.8M | Increased from $90.2M in Q2 2024, indicating widening losses. |
| Total Revenue | $4.5M | Decreased from $5.1M in Q2 2024, showing a decline in sales. |
| Six-Month Net Loss | $209.5M | Increased from $180.1M in the prior year, reflecting sustained unprofitability. |
| Product Revenue | $3.8M | Decreased from $4.5M in Q2 2024, highlighting a core business challenge. |
| Fiscal Year End | 2024-12-31 | Reporting period for executive compensation |
| Filing Date | 20250430 | Date the DEF 14A was filed with the SEC |
| Report Period End Date | 2024-03-31 | Conformed Period of Report |
| Quarter Start Date | 2024-01-01 | 2024 Q1 |
| Previous Year End Date | 2023-12-31 | Fiscal Year End |
| Annual Meeting Date | June 11, 2024 | 2024 annual meeting of stockholders |
| Annual Meeting Time | 9:30 a.m. Pacific Time | 2024 annual meeting of stockholders |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Immunitybio, Inc. (IBRX)?
Immunitybio, Inc. has 35 recent SEC filings from Jan 2024 to May 2026, including 24 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IBRX filings?
Across 35 filings, the sentiment breakdown is: 1 bearish, 31 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Immunitybio, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Immunitybio, Inc. (IBRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Immunitybio, Inc.?
Key financial highlights from Immunitybio, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IBRX?
The investment thesis for IBRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Immunitybio, Inc.?
Key executives identified across Immunitybio, Inc.'s filings include Dr. Patrick Soon-Shiong, Dr. Richard Adkerson.
What are the main risk factors for Immunitybio, Inc. stock?
Of IBRX's 29 assessed filings, 1 were flagged high-risk, 18 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Immunitybio, Inc.?
Forward guidance and predictions for Immunitybio, Inc. are extracted from SEC filings as they are enriched.